Trials / Terminated
TerminatedNCT01230970
Exploratory Study to Assess the Short Term Intratumoural and Peripheral Effects of BN83495 in Postmenopausal Women With Newly Diagnosed Breast Cancer
A Phase II, Open-label, Exploratory Study to Assess the Short Term Intratumoural and Peripheral Effects of BN83495 Administered for 14 Days Prior to Surgery to Postmenopausal Women With Newly Diagnosed Primary Invasive Oestrogen Receptor Positive Breast Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- Female
- Age
- 55 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This trial will assess the intratumoural pharmacological activity of BN83495 by changes in intratumoural levels of sex hormones and associated inhibition of steroid sulphatase (STS) activity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BN83495 | 40mg tablet oral daily administration from Day 1 to Day 14. |
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2011-05-01
- Completion
- 2011-05-01
- First posted
- 2010-10-29
- Last updated
- 2019-01-07
Locations
1 site across 1 country: Norway
Source: ClinicalTrials.gov record NCT01230970. Inclusion in this directory is not an endorsement.